Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angiotech anti-microbial catheters

This article was originally published in The Gray Sheet

Executive Summary

Vancouver firm initiates a 600-patient trial of drug-coated central venous catheter Jan. 5. The product, which will be submitted to FDA for 510(k)-clearance, is designed to prevent infections in critically ill patients with catheters inserted for extended periods. Angiotech describes the drug, 5-fluorouracil, as a "non-traditional anti-infective" because it is chemically different from currently used antibiotics, and, therefore, does not contribute to resistance to such drugs. Once enrollment is complete, the study, which will compare the product to an already approved anti-infective catheter, will take no more than 21 days, Anigotech says...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT023071

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel